March 18 (Bloomberg) -- Genzyme Corp. said it expects a shortage of its thyroid medicine Thyrogen because of a manufacturing issue.
The Cambridge, Massachusetts-based company said in a statement on its website today that it is warning doctors to prepare for a shortage of Thyrogen in the U.S. from mid-April to Mid-June. The European Medicines Agency also said today it was informed by Genzyme of a possible supply shortage. The global supply is expected to fluctuate through July, Genzyme said.
Thyrogen, used in the treatment of thyroid cancer, had sales of $182 million last year, or 4.5 percent of Genzyme’s revenue. The shortage won’t be material to earnings, according to Erin Emlock, a company spokeswoman. Genzyme is being acquired by Paris-based Sanofi-Aventis SA.
To contact the editor responsible for this story: Adriel Bettelheim at firstname.lastname@example.org.